132874-06-7

Usage

Uses

Used in Organic Synthesis:
Methyl 3-(bromomethyl)-2-nitrobenzoate is used as a reagent in organic synthesis for the introduction of a bromomethyl group onto other molecules. This property makes it valuable in the creation of various organic compounds and intermediates.
Used in Pharmaceutical Production:
In the pharmaceutical industry, methyl 3-(bromomethyl)-2-nitrobenzoate is utilized as an intermediate in the synthesis of various drugs. Its ability to introduce a bromomethyl group allows for the development of new pharmaceutical compounds with specific therapeutic properties.
Used in Agrochemical Production:
Similarly, in the agrochemical sector, methyl 3-(bromomethyl)-2-nitrobenzoate is employed as an intermediate for the synthesis of various agrochemicals. Its role in introducing a bromomethyl group contributes to the development of effective pesticides, herbicides, and other agricultural products.
Safety Precautions:
Given its hazardous nature, it is essential to handle methyl 3-(bromomethyl)-2-nitrobenzoate with care. Proper safety measures, including the use of personal protective equipment, should be taken to minimize potential health hazards. Additionally, it is crucial to follow established guidelines and regulations for the safe storage, transportation, and disposal of methyl 3-(bromomethyl)-2-nitrobenzoate.

Upstream product

• 5471-82-9 methyl 3-methyl-2-nitrobenzoate 
• 5437-38-7 3-methyl-2-nitrobenzoic acid 

Downstream Products

• 681430-73-9 3-[(tert-butoxycarbonylmethylamino)-methyl]-2-nitro-benzoic acid methyl ester 
• 138229-59-1 3-formyl-2-nitrobenzoic acid methyl ester 
• 857870-39-4 methyl 3-dimethylaminomethyl-2-nitrobenzoate 
• 857870-03-2 methyl 3-(methoxymethyl)-2-nitrobenzoate 
• 1246443-44-6 tert-butyl 4-{[3-(methoxycarbonyl)-2-nitrobenzylidene]amino}-4-methylpiperidine-1-carboxylate 
• 952479-61-7 methyl 2-nitro-3-[(phenylimino)methyl]benzoate 
• 952479-62-8 methyl 2-phenyl-2H-indazole-7-carboxylate 
• 1618636-71-7 C₃₂H₃₈N₈O₅ 
• 1618636-70-6 C₁₇H₂₅N₅O₄ 
• 1618636-69-3 C₈H₇N₃O₃ 
• 1618636-68-2 C₉H₉N₃O₃ 
• 253120-48-8 methyl 2-amino-3-(hydroxymethyl)benzoate 
• 1331954-75-6 C₉H₉NO₅ 
• 1248731-42-1 methyl 2-amino-3-(methoxymethyl)benzoate 

Relevant academic research and scientific papers

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

Polyheterocyclic substituted pyrimidines or pyridylamine derivatives Composition and medical application thereof

The invention discloses a polycyclic substituted pyrimidine or pyridine amine derivative, and the structure is shown in a formula (I). The invention further discloses a pharmaceutically acceptable salt of the derivative, a solvate, a stereoisomer, a prodrug, a pharmaceutical composition and and an application thereof in medicine. The compounds of the present invention have significant adenosine A. 2A Receptor and/or adenosine A2B The receptor antagonism activity is very practical.

Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials

A phenotypic high-throughput screen allowed discovery of quinazolinone-2-carboxamide derivatives as a novel antimalarial scaffold. Structure-activity relationship studies led to identification of a potent inhibitor 19f, 95-fold more potent than the origin

Derivative based on PARP inhibitor Niraparib and a preparation method and use thereof

The invention discloses a derivative based on a PARP inhibitor Niraparib. The derivative has a structure shown in a formula I as shown in the description, wherein R1 is selected from alkyl, alkoxy, cycloalkyl, aryl alkyl, cycloalkyl alkyl, heterocyclyl, a

SINGLE MOLECULE COMPOUNDS PROVIDING MULTI-TARGET INHIBITION OF PARP AND OTHER PROTEINS AND METHODS OF USE THEREOF

The invention relates to compounds useful for inhibiting PARP and at least one other protein and to methods of treating diseases including cancer by administration of a compound(s) of Formula I-V (or pharmaceutically acceptable salts thereof) as defined herein.

Chemoselective reduction and self-immolation based FRET probes for detecting hydrogen sulfide in solution and in cells

Hydrogen sulfide (H2S) has been regarded as the third gaseous transmitter. Based on the mechanism of chemoselective azido reduction and self-immolation, five fluorescence resonance energy transfer (FRET) probes for the detection of H2S were designed and synthesized. The effect of functional substitution of the self-immolative moiety on azido reduction and quinone-methide rearrangement were investigated. Their fluorescence responses and chemoselectivity for H2S detection were evaluated in solutions and in cells. This strategy may provide a general route for designing H 2S probes with many commercially available FRET pairs. the Partner Organisations 2014.

Development of a fit-for-purpose large-scale synthesis of an oral PARP inhibitor

Compound (1) a poly(ADP-ribose)polymerase (PARP) inhibitor has been made by a fit-for-purpose large-scale synthesis using either a classical resolution or chiral chromatographic separation. The development and relative merits of each route are discussed,

PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE

The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA -damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

We disclose the development of a novel series of 2-phenyl-2H-indazole-7- carboxamides as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.